Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT-8B: Adjuvant chemotherapy with or without nadroparin in high-risk resected NSCLC
2007-002608-16Phase 3Active
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of nadroparin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: recurrence-free survival. Started Jul 2009; status: active.
02
Drugs
nadroparin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-002608-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002608-16.